Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
International Extranodal Lymphoma Study Group (IELSG) |
---|---|
Information provided by: | International Extranodal Lymphoma Study Group (IELSG) |
ClinicalTrials.gov Identifier: | NCT00210366 |
The main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.
Condition | Intervention | Phase |
---|---|---|
Lymphoma, B-Cell |
Drug: Idarubicin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: Andres JM Ferreri, MD | +39 02 2643 ext 7649 | ferreri.andres@hsr.it |
Italy | |
Servizio Radiochemioterapia - Ospedale San Raffaele | Recruiting |
Milan, Italy, 20132 | |
Contact: Andres JM Ferreri +39 022643 ext 7649 andres.ferreri@hsr.it |
Study Chair: | Andres JM Ferreri, MD | San Raffaele Hospital - HSR Servizio di radiochemioterapia |
Study ID Numbers: | IELSG21 |
Study First Received: | September 13, 2005 |
Last Updated: | October 16, 2006 |
ClinicalTrials.gov Identifier: | NCT00210366 |
Health Authority: | Italy: Ministry of Health |
Lymphoma, B-Cell Lymphatic Diseases Idarubicin Immunoproliferative Disorders B-cell lymphomas |
Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Central nervous system lymphoma, primary |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Antineoplastic Agents |
Therapeutic Uses Antibiotics, Antineoplastic Pharmacologic Actions |